The FDA just dropped the age floor on CRISPR medicine. On Wednesday, regulators expanded approval for Casgevy (exa-cel) — the first therapy built with CRISPR/Cas9 gene editing — to children as young as 2 years old with severe sickle cell disease or transfusion-dependent beta thalassemia. Previously capped at patients 12 and up, the move opens treatment to toddlers before irreversible organ damage sets in. The decision follows trial data showing all...